ABSTRACT
ObjectiveTo study the current status and development trend of research on the executive function in overweight or obesity， and to grasp the research hotspots in this field. MethodsA total of 1 321 literatures relevant to the executive function in overweight or obesity collected in Web of Science Core Collection database from 2010 to 2021 were selected. CiteSpace and VOSviewer were used to generate knowledge graphs for visualization analysis， then the number of articles issued， countries/regions， institutions and the co-occurrence， clustering and burst of keywords were analyzed. Results①In terms of the trend of the number of articles issued from 2010 to 2021， the annual quantity of published articles about the executive function in overweight or obesity presented a rapid growth over 2010-2014， then entered into a slow growth stage over 2014-2017， and emerged a rapid growth over 2017-2021. ②From the perspective of countries / regions， a total of 64 countries and regions participated in the research. The largest number of articles issued in this field was the USA， which had the most frequent cooperation and exchanges with other countries and regions， and exerted the greatest academic influence， occupying the core position of this research field. ③From the perspective of research institutions， a total of 1 627 institutions participated in this research field， among which the Illinois University published the most papers and closely cooperated with many productive institutions， forming a research group with a certain scale. ④From the perspective of keywords， the research content mainly involved dietary behavior research， prevention and intervention research， risk factor assessment， and analysis of the characteristics of different groups. ConclusionResearches on executive function in overweight or obesity have been developing rapidly， attracting international attention and covering a wide range of areas.
ABSTRACT
Objective@#To evaluate the efficacy and safety of low dose sublingual nifedipine dripping pills (5 mg) in treating moderate and severe hypertension in comparison with normal dose (10 mg) of sublingual nifedipine dripping pills.@*Methods@#This study was designed as a randomized, double-blind, positive drug parallel controlled, multi-center, non-inferiority clinical trial. Patients with moderate and severe hypertension were enrolled by 14 clinical trial centers, randomly divided into the trial group (sublingual 5 mg nifedipine dripping pills) and the control group (sublingual 10 mg nifedipine dripping pills). The changes in blood pressure were monitored continuously within 2 hours after the initial administration, repeated the dose in 20 minutes interval after the initial administration for up to additional 3 doses (maximum 4 doses) if the antihypertensive efficacy was not satisfactory. The efficacy of antihypertensive therapy between the two groups was evaluated by repeated administration rates and blood pressure changes at 60 minutes post the initial administration, and the safety of treatment was evaluated by recording adverse event rate of the two groups.@*Results@#The anti-hypertensive effective rates at 60 minutes after sublingual administration were 83.5% (202/242) and 86.7% (208/240) respectively between the trial group and control group (χ2=1.307, P=0.253) . On the aspect of antihypertensive effectiveness at 60 minutes after single dose of sublingual administration, the anti-hypertension effective rates of the trial group and the control group were 85.6% (154/180) and 87.2% (164/188) respectively (χ2=0.221, P=0.639). Prevalence of the repeated administration was also similar between the two groups (25.6%(62/242) in the trial group and 21.7% (52/240) in the control group, χ2=1.043, P=0.307). On the safety aspect, there was no adverse events/reactions in the trial group, but there were 15 cases of adverse events/reactions occurred in control group (6.25%, χ2=15.611, P<0.001).@*Conclusions@#In the treatment of moderate to severe hypertension, the antihypertensive efficacy of low dose nifedipine dripping pills is similar to that of conventional dosage, and the safety profile of low dose nifedipine dripping pills is better than that of the conventional dose.
ABSTRACT
Objective To study whether the contrast volume and radiation dose can be reduced by automated contrast injection system(ACIS) in coronary angiography compared with manual contrast injection system(MCIS).Methods 200 patients undergoing coronary angiography with transradial approach in the People′s Hospital of Liaoning Province were enrolled in the study from January 2016 to June 2016.They were divided into the ACIS group (n=100) and the MCIS group (n=100).The clinical data, the net amount of contrast the total amount of contrast media consumed, number of angiographic views performed, fluoroscopy time, air kerma (AK) and dose area product (DAP) of the two groups were statistically analyzed.Results There were no statistical differences in the clinical data, the net amount of contrast used, number of angiographic views performed and fluoroscopy time between the two groups (all P>0.05).The total amount of contrast media used, AK, and DAP were less in the ACIS group than in the MCIS group (all P<0.05).Conclusions The volume of contrast consumption and radiation dose can be reduced by ACIS during coronary angiography with transradial approach compared to MCIS.
ABSTRACT
Objective To compare the efficiencies of imatinib and dasatinib in patients with chronic myeloid leukemia-chronic phase (CML-CP).Methods The databases were retrieved,including Cochrane Library,OVID,Embase,PubMed,China National Knowledge Infrastructure (CNKI),WanFang database and VIP database,besides,references of articles were further to search.The quality of randomized controlled trials (RCTs) was assessed by the Cochrane collaboration' s risk tool.Meta-analysis was performed by RevMan 5.1 software.Results A total of 5 articles involved 2 031 patients with CML-CP were included.Meta-analysis showed that the rate of complete cytogenetic response (CCyR) at the 12th month in dasatinib group was higher than that in imatinib group [83.6 ％ (478/572) vs 70.6 ％ (406/575),OR =2.11,95 ％ CI 1.59-2.80,P＜ 0.05],and the rate of major molecular response (MMR) at the 12th month in dasatinib group was higher than that in imatinib group [49.3 ％ (296/600) vs 30.6 ％ (185/605),OR =2.22,95 ％ CI 1.75-2.82,P ＜ 0.05].Conclusion Dasatinib can improve CCyR and MMR rate at the 12th month in CML-CP patients.
ABSTRACT
Objective To estimate the efficacy and safety of Voriconazole as antifungal prophylaxis of invasive fungal infection ( IFI) for malignant hematology patients. Methods The randomized controlled trials of Voriconazole treatment in invasive fungal infection for malignant hematology patients (ended in September 2014) were searched from Cochrane library, Medline, Embase, Pubmed, CBM, CNKI, Blood database. The meta analysis were performed by RevMan5.0. Results Ten literatures reported in 1 773 cases, in which there was significantly difference in effective rate between Voriconazole and other antifungal agents such as Amphotericin-B, Itraconazole, Micafungin and Fluconazole(P < 0.000 01); Four literatures indicated that there was significantly difference in adverse event rate between Voriconazole and amphotericin-B (P < 0.00 001); no significantly difference in adverse event rate between Voriconazole and amphotericin-B(P = 0.57); no significantly difference in adverse event rate between Voriconazole and Micafungin (P = 0.69); no significantly difference in adverse event rate between Voriconazole and Fluconazole (P = 0.70); Subgroup analysis indicated that adverse event rate between Voriconazole and Itraconazole is P=0.001, P = 0.17 respectively. Conclusion Voriconazole showed relative high efficient and low toxicity characteristics in treatment of malignant hematology accompanied by invasive fungal infection. But with its widely clinical application, the clinical value of Voriconazole needs to be further tested.
ABSTRACT
Objective To summarize the safety and clinical therapeutic effect of advanced aged coronary heart disease(CHD) patients with angina recurrence after coronary artery bypass grafting (CABG).Methods The clinical data,arteriography and the interventional results of 9 aged patients with angina recurrence treated by CABG were retrospectively analyzed .Results There were 8 patients received intervention ,among them 5 patients received coronary artery intervention , another 3 patients received graft vessels intervention .During operation and hospitaliza-tion,angina recurrence,acute myocardial infarction,revascularization,complication and mortality were not observed in 8 patients who received intervention .All patients were followed up for 12 months,there were 3 patients had angina recurrence and cured by drugs , but had no acute myocardial infarction and revascularization .Conclusion The intervention for advanced aged patients after CABG is a safe and effective treatment .The advanced aged patients with angina recurrence need receive arteriography quickly and receive coronary artery interventional treatment or graft vessels interventional treatment .
ABSTRACT
Objective To investigate the effectiveness and safety in pediatric patients (Age≤14 years) with hypertrophic obstructive cardiomyopathy (HOCM) treated by percutanous transluminal septal myocardial ablation (PTSMA). Methods Retrospectively analyzed the data from four pediatric(age≤14 years) patients with HOCM treated by PTSMA from March 2004 to June 2012, including their clinical data, coronary angiography and the results of PTSMA to evaluate the complication and clinical outcome after PTSMA. Results The left ventricular outlfow tract pressure gradient (LVOTPG) at rest decreased after operation when compared with pre-lablation level (32.0 mm Hg vs 80.0 mm Hg, P>0.05). The LVOTPG after premature beat decreased with signiifcant difference after ablation (40.0 mm Hg vs 122.5 mm Hg, P<0.05). During opration and hospitalization, 1 patient developed right bundle branch block, and another patient developed complete atrioventricular block, Both patients’ arrhythmia received after temporary pacing and medical treatment. No death and major clinical adverse event recorded after operation and during the 12 months follow up. Conclusions PTSMA was effective and safe for children with HOCM.
ABSTRACT
<p><b>BACKGROUND</b>First generation drug-eluting stents (DES) were associated with a high incidence of late stent thrombosis (ST), mainly due to delayed healing and re-endothelization by the durable polymer coating. This study sought to assess the safety and efficacy of the Nano polymer-free sirolimus-eluting stent (SES) in the treatment of patients with de novo coronary artery lesions.</p><p><b>METHODS</b>The Nano trial is the first randomized trial designed to compare the safety and efficacy of the Nano polymer-free SES and Partner durable-polymer SES (Lepu Medical Technology, Beijing, China) in the treatment of patients with de novo native coronary lesions. The primary endpoint was in-stent late lumen loss (LLL) at 9-month follow-up. The secondary endpoint was major adverse cardiac events (MACE), a composite of cardiac death, myocardial infarction or target lesion revascularization.</p><p><b>RESULTS</b>A total of 291 patients (Nano group: n = 143, Partner group: n = 148) were enrolled in this trial from 19 Chinese centers. The Nano polymer-free SES was non-inferior to the Partner durable-polymer DES at the primary endpoint of 9 months (P < 0.001). The 9-month in-segment LLL of the polymer-free Nano SES was comparable to the Partner SES (0.34 ± 0.42) mm vs. (0.30 ± 0.48) mm, P = 0.21). The incidence of MACE in the Nano group were 7.6% compared to the Partner group of 5.9% (P = 0.75) at 2 years follow-up. The frequency of cardiac death and stent thrombosis was low for both Nano and Partner SES (0.8% vs. 0.7%, 0.8% vs. 1.5%, both P = 1.00).</p><p><b>CONCLUSIONS</b>In this multicenter randomized Nano trial, the Nano polymer-free SES showed similar safety and efficacy compared with the Partner SES in the treatment of patients with de novo coronary artery lesions. Trials in patients with complex lesions and longer term follow-up are necessary to confirm the clinical performance of this novel Nano polymer-free SES.</p>
Subject(s)
Aged , Female , Humans , Male , Middle Aged , Coronary Artery Disease , Drug Therapy , General Surgery , Drug-Eluting Stents , Immunosuppressive Agents , Therapeutic Uses , Prospective Studies , Sirolimus , Therapeutic UsesABSTRACT
<p><b>BACKGROUND</b>Drug-eluting stents (DES) with durable polymer have significantly reduced restenosis and target vessel revascularization compared with bare metal stents. Durable polymer has been linked with persistent inflammation of vessel wall and delayed endothelial healing that may increase the risk of late and very late stent thrombosis. This study sought to evaluate the efficacy and safety of HELIOS completed biodegradable polymer sirolimus-eluting stent (SES) in de novo coronary lesions.</p><p><b>METHODS</b>Totally, 287 patients with one or two de novo coronary lesions (lesion length ≤ 38 mm and reference vessel diameter 2.5-4.0 mm) were enrolled in the HOPE study, a prospective, multicenter, randomized, non-inferiority trial. Patients were randomized to treatment either with HELIOS completed biodegradable polymer SES (n = 142) or PARTNER durable polymer SES (n = 145). The primary endpoint was angiographic in-stent late lumen loss (LLL) at 9-month follow-up. The secondary endpoint included stent thrombosis and major adverse cardiac events including cardiac death, myocardial infarction (MI) and target lesion revascularization (TLR).</p><p><b>RESULTS</b>The 9-month in-stent LLL in the HELIOS group was similar to the PARTNER group, (0.16 ± 0.22) mm vs. (0.19 ± 0.30) mm (P = 0.28). The difference and 95% confidence interval were -0.03 (-0.09, 0.04), and the P value for non-inferiority <0.01. Major adverse cardiovascular event (MACE) occurred in 7.9% vs. 8.2%, MI in 2.4% vs. 3.0%, TLR in 5.5% vs. 3.0%, and stent thrombosis in 0 vs. 1.5%; and events were comparable between the HELIOS group and PARTNER group at three-year follow-up (all P > 0.05). The three-year cardiac death was lower in the HELIOS group, but with no significant difference, 0 vs. 3.0% (P = 0.12).</p><p><b>CONCLUSIONS</b>In the HOPE trial, the novel completed biodegradable polymer SES HELIOS was non-inferior to the durable polymer SES PARTNER with respect to nine-month in-stent LLL in de novo coronary lesions. The incidence of other clinical endpoints was low for both of the stents in three-year follow-up.</p>
Subject(s)
Adult , Aged , Humans , Middle Aged , Young Adult , Angiography , Coronary Artery Disease , General Surgery , Coronary Restenosis , Drug-Eluting Stents , Percutaneous Coronary Intervention , Polymers , Chemistry , Therapeutic Uses , Sirolimus , Therapeutic Uses , Titanium , Chemistry , Treatment OutcomeABSTRACT
Objective To investigate the effect of ginsenosides-Rb1(Gs-Rb1) on doxorubicin (Dox)-induced heart failure (HF), and the related mechanisms of connexin 43 (CX43) thereof. Methods Rats with Dox-induced HF were ran-domly divided into Dox group (n=15) and Gs-Rb1 group (n=17), and the health age-matched rats were as control (n=15). In addition, cardiomyocytes were randomly divided into Dox group, Gs-Rb1 group and control group. After the intervention, echocardiography or apoptotic ratio (AR) was analyzed, respectively. The expression levels of p21-activated kinase 1 (PAK1), protein phosphatase type 2A (PP2A) and CX43 were detected by Western bolt or RT-PCR analysis, respectively. Re-sults Gs-Rb1 significantly improved heart function in rats with HF, decreased left ventricular mass index and inhibited the cell apoptosis induced by Dox. Both mRNA and protein expressions of CX43 were significantly decreased in Dox group than those of control group. The expression of CX43 was significantly increased in Gs-Rb1 group, which was significantly lower than that of control group. There was no significant difference in PAK1 between Dox group and control group (P>0.05). The expression of PAK1 was significantly up-regulated by Gs-Rb1. The PP2A protein was significantly up-regulated in Dox group than that of control group, which was significantly higher in Gs-Rb1 group than that of Dox group. Conclusion Gs-Rb1 improved HF by adjusting CX43, which may be mediated by PAK1-PP2A.
ABSTRACT
Objective To investigate the therapeutic effects of sinus tachycardia patients with atypical asthma.Methods The data of 19 patients with sinus tachycardia resulted from atypical asthma,including clinical data and the treatment results were retrospectively analyzed.Results There were 19 patients received lung function check,among them total 19 patients were atypical asthma whose tachycardia were cured,the heart beating rate was significantly lower after treated [(86.79±3.91) vs (108.89±4.23),t=6.921,P=0.000].Condusion The lung function check was requisite for patients with sinus tachycardia resulted from atypical asthma and the tachycardia can be cured by curing asthma drugs and calcium channel blocking agent.
ABSTRACT
Objective To investigate the effect of autologous coronary intervention in patients with angina recurrence of graft vessels occlusion after coronary artery bypass graftting(CABG).Methods Retrospectively analyzed the data of 10 patients with angina recurrence because of graft vessels occlusion.treated by CABG,including in clinical data,arteriography and the interventional results.Results Among 10 patients,9 patients received chronic total occlusion(CTO) PCI,another 1 patients received left main stem(LM) intervention.There were none had angina recurrence after PCI in 10 patients.Conclusion Conclusion Autologous coronary intervention in patients with angina recurrence of graft vessels occlusion after coronary artery bypass graftting was the safety and effective treatment.
ABSTRACT
ObjectiveTo investigate the short-term and long-term interventional therapeutic effect of coronary heart disease(CHD)patients with angina recurrence after coronary artery bypass grafting(CABG). MethodsThe data of patients with angina recurrence treated by CABG,including clinical data,arteriography and the interventional results were retrospectively analyzed. Results There were 12 patients received intervention,among them 6 patients received coronary artery intervention,another 6 patients received graft vessels intervention.During operation and hospitalization,among 12 patients there were none had angina recurrence,acute myocardial infarction,revascularization and mortality.The total 12 patients were followed for 9 ～ 21months,there were two patients had angina recurrence cured by drugs,but none with mortality,acute myocardial infarction and revascularization. ConclusionThe intervention for patients with angina recurrence after grafting was a safe and effective treatment.
ABSTRACT
Objective To explore the feasibility and safety of right ventricular septal pacing with active fixation electrodes.Methods This was a randomized and control clinical trial.Patients implanted with pacemaker were randomly divided into two groups.One group underwent the right ventrieular high septal pacing with the active fixation electrodes(RVS group),and the other group underwent the right ventricular apical pacing with the passive fixation electrodes(control group).The parameter was recorded in two groups in and after operation and compared accordingly.Results (1)There were no significant differences in the procedure time between two groups[averaged(59.6±3.2)and(60.2±3.7)minutes respectively].But the time of exposing X-ray was significant longer in RVS group.(2)There was no significant difference in acute implanting measurement,except perioperative and postoperative threshold 1 month in RVS group was higher than that in control group(P＜0.05 or＜0.01).After 3 months,there was no significant difference.(3)Impedance decreased significantly in 1 month and 3 months in RVS group[P＜0.01 or＜0.05).(4)There was no difference in R-wave sensing between two groups.(5)After 100%pacing,the mean QRS duration Was shorter in RVS group,but the difference was not significant.(6)Operations in two groups came off smoothly and there were no complications.Conclusion It is feasible and secure to pace from RVS with active fixation electrodes.
ABSTRACT
Objective To investigate the electrocardiographic(ECG) characteristics and assess the safety of radiofrequency catheter ablation (RFCA) of ventricular tachyeardia (VT), and frequent ventricular premature con- tractious(VPCs) originating from left ventricular outflow tract(LVOT). Methods Twelve-lead ECG analysis and RFCA were performed in 9 patient with VT or VPCs originating from LVOT. Results The sites to be successfully ablated were in left valsalva sinus in 6 patients,and subaortic valve in 3 patient. ECG revealed tall R wave in leads Ⅱ, Ⅲ ,aVF, V5 and V6. QS morphology in both leads aVR and aVL,QS morphology in lead Ⅰ in most cases. R wave in lead Ⅰ was relative tall, the R/S wave amplitude in lead V1 was over 0.62 ,and precordia R wave transition was irregular. All 9 patients were successfully ablated. No death or recurrenced case during follow-up. Conclusion Ventricular taehycardia and frequent ventricular premature rcontractions originating from left ventricutar outflow tract could be known by some specific ECG characteristics and could be radically treated safely by RFCA.
ABSTRACT
OBJECTIVE:To investigate release characteristics of sirolimus liposome in vitro.METHODS:The concentration of sirolimus was determined by RP-HPLC.In vitro release rate of sirolimus liposome within 24 h was investigated by the reverse dialysis method with 20% ethanol 500 mL as medium.Release curve of sirolimus was fitted with drug release model equation.RESULTS:The linear range of sirolimus were 0.5～20 ?g.mL-1(r=0.999 8)with an average recovery of 99.42%(RSD=1.23%).At the first 4 hours of release,sirolimus liposome released rapidly with accumulative release rate of 50%.After that release rate of liposome was slowed down with accumulative rate of 80% in 24 h.The in vitro release curve conformed to the first order equation.CONCLUSION:Sirolimus liposome has delayed release capability,and in vitro drug release of sirolimus liposome is in concentration dependant manner.
ABSTRACT
Objective To evaluate left ventricular function in patients with acute myocardial infarction(AMI)by autologous peripheral blood stem cells(PBSCs)transplantation with echocardiography.Methods Patients with AMI were randomly assigned to receive intracoronary PBSCs transplantation following bone marrow cells mobilization(standard drug therapy and PCI,PBSCs transplantation group,n=35)or only receive standard therapy(standard drug therapy and PCI,n=34).Echocardiography were performed before and 6 months after treatment.Results LV function was significantly improved 6 months after G-CSF mobilized autologous PBSCs transplantation compared to baseline(P
ABSTRACT
Objective Observed the mobilization effects、 the safety and feasibility of autologous circulating blood stem cell by G-CSF in acute myocardial infarction (AMI). Methods 45 patients with AMI were randomly allocated to receive either inclusive type Granulocyte Colony-Stimulating Factor (G-CSF), to mobilize the stem cell. The patients received the dose of G-CSF 300?g-600?g/day, by hypodermic injection, and the duration of applying G-CSF was 5 days. In the process of the mobilization of the circulating blood stem cell, prior to applying G-CSF and on the 3rd、4th、5th、6th、7th after applying G-CSF, the white blood cell (WBC) and CD34+ cell count in the circulating blood should be observed; and the following side effects also should be paid attention to, such as: bone pain, tetter, fever, gastrointestinal effects( nausea 、vomit、 coprostatis ),deteriorated of angina or heart failure and some rare effects(spontaneous spleen rupture, severe purulent infection, hypercoagulable state, autologous immune diseases). Results Prior to applying G-CSF and the 3rd、4th、5th、6th、7th after applying G-CSF, the counts of WBC were (8.42?2.59)?10 9/L、(31.28?8.34)?10 9/L、(35.24?9.38)?10 9/L、(37.03?13.07)?10 9/L、(35.34?14.68)?10 9/L、(20.35?9.22)?10 9/L;the counts of CD34+ cell were (14.89?11.46)?10 6、(67.78?50.88)?10 6、(124.79?136.13)?10 6、(208.92?206.97)?10 6、(206.10?184.57)?10 6、(66.63?56.56)?10 6;The peak of curve that WBC and CD34 + cell count changed with applying days was on the 5th .The count of CD34 + cell in the circulating blood was positive referent with the count of WBC in the circulating blood(r=0.835);was not reference with age、 sex、body weight、and the onset time of AMI. There were total 17 complications during the mobilization of circulating blood stem cell. The incidence of complications during mobilization is 37.8%(17/45), including bong pain being 15.6%(7/45)、fever being 6.7 %(3/45)、pale being 4.4 %(2/45)、tetter being 4.4 %(2/45)、deterioration of heart failure being 4.4 %(2/45),spleen thrombosis being 2.2 %(1/45).No death happened. Conclusion : In patients with AMI, the mobilized peak of WBC and CD34 + cell counts changed with applying days was at the 5th, and the count of CD34 + cell in the circulating blood was positive referent with the count of WBC in the circulating blood(r=0.940),was negative referent with body weight of patients(r=-0.398). And mobilization of autologous circulating blood stem cell was feasible and safe.
ABSTRACT
Objective We Observed the mobilization effects of autologous circulating blood stem cell by G-CSF in old patients(≥70 years old) with acute myocardial infarction (AMI).Methods 10 old patients with AMI were allocated to receive either inclusive type Granulocyte Colony-Stimulating Factor (G-CSF), or excrete type G-CSF to mobilize the stem cell, with either 300?g/day or 600?g/day. The patients received G-CSF by hypodermic injection, and the duration of applying G-CSF was 5 days. In the process of the mobilization of the circulating blood stem cell, the white blood cell (WBC) and CD34 + cell count in the circulating blood should be observed. Results Prior to applying G-CSF and the 3rd、4th、5th、6th、7th after applying G-CSF, the counts of WBC were 6.75?10 9/L、28.16?10 9/L、34.93?10 9/L、34.40?10 9/L、38.93?10 9/L、21.85?10 9/L; the counts of CD34+ cell were 6.25?10 6、51.10?10 6、92.60?10 6、109.65?10 6、134.69?10 6、45.09?10 6 The peak of curve that WBC and CD34 + cell count changed with applying days was at the 6th .The count of CD34 + cell in the circulating blood was positive referent with the count of WBC in the circulating blood(r=0.940)Conclusion In old patients with AMI, the mobilized peak of WBC and CD34 + cell counts changed with applying days was at the 6th, and the count of CD34 + cell in the circulating blood was positive referent with the count of WBC in the circulating blood.
ABSTRACT
<p><b>OBJECTIVE</b>To assess the complications of percutaneous tansluminal septal myocardial ablation (PTSMA) for the treatment of hypertrophic obstructive cardiomyopathy (HOCM).</p><p><b>METHODS</b>Seventy-two patients with symptomatic left ventricular outflow tract obstruction were diagnosed by echocardiography or catheterization procedures. Absolute ethanol was injected into the target coronary artery branch (branches) for septal myocardial ablation. Documented complications were recorded.</p><p><b>RESULTS</b>Sixty-nine patients had severe chest pain, 19 developed different degrees of heart block during the periprocedural period, but only one developed a complete AV block, requiring permanent pace-maker implantation. Temporary right bundle branch block occurred in 50% of patients and permanent block occurred in 38.9% of patients. Acute inferior myocardial infarction occurred in six patients (8.3%) and acute anterior myocardial infarction occurred in one patient. During two-year follow-up of 24 cases, there were no deaths. All patients had improvement in heart function and none experienced heart failure.</p><p><b>CONCLUSION</b>The most common complication of PTSMA is right bundle branch block. The most significant complication of the procedure is heart block. PTSMA is a good technical, non-surgical treatment for HOCM.</p>